All Stories

  1. A deep-learning based biomarker of systemic cellular senescence burden to predict mortality and health outcomes
  2. High‐Frequency, At‐Home Monitoring of Drug Safety and Tolerability in Clinical Trials: Results From Studies of Fluvoxamine for COVID‐19 Treatment
  3. Major depressive disorder as a driver of premature aging
  4. CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression
  5. Comparing Treatment Approaches for Older Adults with Treatment-Resistant Depression -- The OPTIMUM Study
  6. Design and feasibility of an Alzheimer’s disease blood test study in a diverse community-based population
  7. Fatness, fitness and the aging brain: A cross sectional study of the associations between a physiological estimate of brain age and physical fitness, activity, sleep, and body composition
  8. Using Implementation Science to Guide the Process of Adapting a Patient Engagement Intervention for Inpatient Spinal Cord Injury/Disorder Rehabilitation
  9. Mindfulness Training for Depressed Older Adults Using Smartphone Technology: Protocol for a Fully Remote Precision Clinical Trial
  10. Optimized, personalized, and digitalized: protocol for a fully-remote precision clinical trial of mindfulness training for depressed older adults using smartphone technology (Preprint)
  11. Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”
  12. Fluvoxamine for Outpatient COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-Analysis
  13. Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence
  14. Perioperative Mental Health in Older Adults: New Research on Epidemiology and Outcomes
  15. Smartphone-Based Ecological Momentary Assessment as the New Standard Measure for Post-Stroke Functioning (Preprint)
  16. Enhancing Cognition in Older Persons with Depression or Anxiety with a Combination of Mindfulness-Based Stress Reduction (MBSR) and Transcranial Direct Current Stimulation (tDCS): Results of a Pilot Randomized Clinical Trial
  17. Comparing stress prediction models using smartwatch physiological signals and participant self-reports
  18. Effect of electroencephalogram-guided anaesthesia administration on 1-yr mortality: follow-up of a randomised clinical trial
  19. Ketamine for Depression in Older Adults
  20. Effect of Early Treatment with Fluvoxamine on Risk of Emergency Care and Hospitalization Among Patients with COVID-19: The TOGETHER Randomized Platform Clinical Trial
  21. Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms
  22. Association Between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID‐19: An Observational Multicenter Study
  23. Postictal generalized electroencephalographic suppression following electroconvulsive therapy: Temporal characteristics and impact of anesthetic regimen
  24. Surgical Complications in Older Adults Predict Decline in Self-Perceived Cognitive Function in the Ensuing Year: A Cohort Study
  25. Acute Symptoms of Mild to Moderate COVID-19 Are Highly Heterogeneous Across Individuals and Over Time
  26. Association between Functional Inhibitors of Acid Sphingomyelinase and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: results from an observational multicenter study
  27. Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response
  28. Executive Function Moderates Functional Outcomes of Engagement Strategies During Rehabilitation in Older Adults
  29. Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression
  30. COVID-19 Clinical Trials: A Voice From the Front Lines
  31. Cortical inhibition, facilitation and plasticity in late-life depression: effects of venlafaxine pharmacotherapy
  32. Going remote: Implementing digital research methods at an academic medical center during COVID-19
  33. Precision clinical trials: a framework for getting to precision medicine for neurobehavioural disorders
  34. Prolactin and Estrogen Levels in Postmenopausal Women Receiving Aripiprazole Augmentation Treatment for Depression
  35. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
  36. Voltage-based automated detection of postictal generalized electroencephalographic suppression: Algorithm development and validation
  37. A Smartphone-Based Technique to Detect Dynamic User Preferences for Tailoring Behavioral Interventions: Observational Utility Study of Ecological Daily Needs Assessment
  38. iTBS to Relieve Depression and Executive Dysfunction in Older Adults: An Open Label Study
  39. The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases
  40. The Effect of Venlafaxine on Electrocardiogram Intervals During Treatment for Depression in Older Adults
  41. A Qualitative Study of Perioperative Depression and Anxiety in Older Adults
  42. Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders
  43. Effectiveness of theory-based digital self-management interventions for improving depression, anxiety, fatigue and self-efficacy in people with neurological disorders: A systematic review and meta-analysis
  44. Pharmacological Treatments for Tinnitus—Reply
  45. Experiences of American Older Adults with Pre-existing Depression During the Beginnings of the COVID-19 Pandemic: A Multicity, Mixed-Methods Study
  46. Hypertension and orthostatic hypotension with venlafaxine treatment in depressed older adults
  47. Effectiveness of non-pharmacological interventions for treating post-stroke depressive symptoms: Systematic review and meta-analysis of randomized controlled trials
  48. Positive information facilitates response inhibition in older adults only when emotion is task-relevant
  49. Older molecular brain age in severe mental illness
  50. Stereoselective Steady‐State Disposition and Bioequivalence of Brand and Generic Bupropion in Adults
  51. Mindfulness, Education, and Exercise for age-related cognitive decline: Study protocol, pilot study results, and description of the baseline sample
  52. Author Correction: Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson’s disease
  53. Augmenting Computerized Cognitive Training With Vortioxetine for Age-Related Cognitive Decline: A Randomized Controlled Trial
  54. Pharmacogenetic Implications for Antidepressant Pharmacotherapy in Late-Life Depression: A Systematic Review of the Literature for Response, Pharmacokinetics and Adverse Drug Reactions
  55. Preoperative Cognitive Abnormality, Intraoperative Electroencephalogram Suppression, and Postoperative Delirium
  56. Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine
  57. Central-positive complexes in ECT-induced seizures: Evidence for thalamocortical mechanisms
  58. Mood Disorders and Dementia: Time for Action
  59. mHealth Assessment and Intervention of Depression and Anxiety in Older Adults
  60. “What Were You Before the War?” Repurposing Psychiatry During the COVID-19 Pandemic
  61. Action at a Distance: Geriatric Research during a Pandemic
  62. Precision Medicine in Clinical Trials
  63. Does patient expectancy account for the cognitive and clinical benefits of mindfulness training in older adults?
  64. Tinnitus
  65. A Smartphone-Based Technique to Detect Dynamic User Preferences for Tailoring Behavioral Interventions: Observational Utility Study of Ecological Daily Needs Assessment (Preprint)
  66. Activity Level and Intensity of Older Adults in Skilled Nursing Rehabilitation Measured via Actigraphy
  67. Neuroticism predicts fear of falling after hip fracture
  68. Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson’s disease
  69. Predicting Remission in Late-Life Major Depression
  70. Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis
  71. A qualitative study of older adults’ perspectives on initiating exercise and mindfulness practice
  72. Comorbid anxiety in late‐life depression: Relationship with remission and suicidal ideation on venlafaxine treatment
  73. Cognitive Training for Optimizing Perioperative Brain Health
  74. Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (OPTIMUM): Study Design and Treatment Characteristics of the First 396 Participants Randomized
  75. Adiposity, Hepatic Triglyceride, and Carotid Intima Media Thickness During Behavioral Weight Loss Treatment in Antipsychotic-Treated Youth: A Randomized Pilot Study
  76. Obsessions are strongly related to eating disorder symptoms in anorexia nervosa and atypical anorexia nervosa
  77. Effect of Enhanced Medical Rehabilitation on Functional Recovery in Older Adults Receiving Skilled Nursing Care After Acute Rehabilitation
  78. Getting to precision psychopharmacology: Combining clinical and genetic information to predict fat gain from aripiprazole
  79. Antidepressant Treatment for Late‐Life Depression: Considering Risks and Benefits
  80. An inverse relationship between cortical plasticity and cognitive inhibition in late-life depression
  81. Emotional Response Inhibition Is Greater in Older Than Younger Adults
  82. Feasibility of Intensive Ecological Sampling of Tinnitus in Intervention Research
  83. When All Else Fails, Listen to the Patient: A Viewpoint on the Use of Ecological Momentary Assessment in Clinical Trials
  84. Pride and Prejudice in the Treatment of Depression and Anxiety in Acutely Ill Older Adults
  85. Diagnostic, clinical, and personality correlates of food anxiety during a food exposure in patients diagnosed with an eating disorder
  86. Crossover to Bilateral Repetitive Transcranial Magnetic Stimulation
  87. Effect of Electroencephalography-Guided Anesthetic Administration on Postoperative Delirium Among Older Adults Undergoing Major Surgery
  88. Bioequivalence and Therapeutic Equivalence of Generic and Brand Bupropion in Adults With Major Depression: A Randomized Clinical Trial
  89. Assessment and treatment of major depression in older adults
  90. Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression
  91. Intraoperative ketamine for prevention of depressive symptoms after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial
  92. Cognitive Improvement in Older Adults in the Year After Hip Fracture: Implications for Brain Resilience in Advanced Aging
  93. Pharmacogenetic Guidelines and Decision Support Tools for Depression Treatment: Application to Late-Life
  94. Assessment of neuroplasticity in late-life depression with transcranial magnetic stimulation
  95. Scientific Biography of a Mid-Career Physician-Scientist: Getting by With Help From My Friends
  96. Stopping Cognitive Decline in Patients With Late-Life Depression: A New Front in the Fight Against Dementia
  97. Executive Function Predicts Antidepressant Treatment Noncompletion in Late-Life Depression
  98. Clinical Predictors of Extrapyramidal Symptoms Associated With Aripiprazole Augmentation for the Treatment of Late-Life Depression in a Randomized Controlled Trial
  99. Meal and snack-time eating disorder cognitions predict eating disorder behaviors and vice versa in a treatment seeking sample: A mobile technology based ecological momentary assessment study
  100. Reduced GABAergic cortical inhibition in aging and depression
  101. Cognitive and Neurophysiological Recovery Following Electroconvulsive Therapy: A Study Protocol
  102. Ability of postoperative delirium to predict intermediate-term postoperative cognitive function in patients undergoing elective surgery at an academic medical centre: protocol for a prospective cohort study
  103. Childhood Trauma Is Associated With Poorer Cognitive Performance in Older Adults
  104. Cognitive Training for Older Adults: What Works?
  105. Integrative Geriatric Psychiatry
  106. Depression and Functional Impairment: A Pernicious Pairing in Older Adults
  107. Electroencephalography-Guided Minimisation of Anaesthetic Administration to Prevent Post-Operative Delirium: A Randomised, Pragmatic Trial
  108. The role of late life depressive symptoms on the trajectories of insomnia symptoms during antidepressant treatment
  109. Effect of Metabolic Syndrome on Late-Life Depression: Associations with Disease Severity and Treatment Resistance
  110. Achieving Milestones as a Prerequisite for Proceeding With a Clinical Trial
  111. Alternative Facts? Antidepressants and Falls in Older Adults
  112. Fear of food prospectively predicts drive for thinness in an eating disorder sample recently discharged from intensive treatment
  113. Effects of Cable News Watching on Older Adults’ Physiological and Self-Reported Stress and Cognitive Function
  114. The role of depression pharmacogenetic decision support tools in shared decision making
  115. Specific depressive symptoms predict remission to aripiprazole augmentation in late‐life treatment resistant depression
  116. Mindfulness-Based Stress Reduction for Older Adults With Stress Disorders and Neurocognitive Difficulties
  117. Potentially Inappropriate Medications and the Time to Full Functional Recovery After Hip Fracture
  118. Evaluation of Ecological Momentary Assessment for Tinnitus Severity
  119. Intraoperative ketamine for prevention of postoperative delirium or pain after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial
  120. Plasma REST: a novel candidate biomarker of Alzheimer’s disease is modified by psychological intervention in an at-risk population
  121. Bone Turnover with Venlafaxine Treatment in Older Adults with Depression
  122. Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults
  123. D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders
  124. Predictors of Posttraumatic Stress Symptoms and Association with Fear of Falling After Hip Fracture
  125. Fear of Falling after Hip Fracture: Prevalence, Course, and Relationship with One-Year Functional Recovery
  126. Enhanced Medical Rehabilitation: Effectiveness of a clinical training model
  127. Telephone-Delivered Stepped Collaborative Care for Treating Anxiety in Primary Care: A Randomized Controlled Trial
  128. Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder
  129. Consequences of Anxiety in Aging and Cognitive Decline
  130. Impact of Prior Treatment on Remission of Late-Life Depression with Venlafaxine and Subsequent Aripiprazole or Placebo Augmentation
  131. Older Adults' Perspectives on Clinical Research: A Focus Group and Survey Study
  132. Gray matter regions statistically mediating the cross‐sectional association of eotaxin and set‐shifting among older adults with major depressive disorder
  133. Self-reported obstructive sleep apnea is associated with nonresponse to antidepressant pharmacotherapy in late-life depression
  134. Unreliability as a threat to understanding psychopathology: The cautionary tale of attentional bias.
  135. Immunological biomarkers associated with brain structure and executive function in late‐life depression: exploratory pilot study
  136. Protocol for the Electroencephalography Guidance of Anesthesia to Alleviate Geriatric Syndromes (ENGAGES) study: a pragmatic, randomised clinical trial
  137. Treatment Emergent Suicidal Ideation in depressed older adults
  138. Use of the Temperament and Character Inventory to Predict Response to Repetitive Transcranial Magnetic Stimulation for Major Depression
  139. Feasibility and Acceptability of Smartphone Assessment in Older Adults with Cognitive and Emotional Difficulties
  140. Cognitive-behavioral therapy augmentation of SSRI reduces cortisol levels in older adults with generalized anxiety disorder: A randomized clinical trial.
  141. Ecological momentary assessment versus standard assessment instruments for measuring mindfulness, depressed mood, and anxiety among older adults
  142. Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression
  143. Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial
  144. Trajectories of depressive symptoms after hip fracture
  145. Getting to More Effective Weight Management in Antipsychotic-Treated Youth: A Survey of Barriers and Preferences
  146. Trajectories of suicidal ideation in depressed older adults undergoing antidepressant treatment
  147. Depression Remission Rates Among Older Black and White Adults: Analyses From the IRL-GREY Trial
  148. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial
  149. Solving the Geriatric Mental Health Crisis in the 21st Century
  150. Antidepressant Response Trajectories and Associated Clinical Prognostic Factors Among Older Adults
  151. Cause or Effect? Selective Serotonin Reuptake Inhibitors and Falls in Older Adults: A Systematic Review
  152. Response to Stubbs's Letter to the Editor
  153. Adiposity and Cardiometabolic Risk in Children With and Without Antipsychotic Drug Treatment
  154. Treating Anxiety Disorders in Older Adults
  155. A new measure of fear of falling: psychometric properties of the fear of falling questionnaire revised (FFQ-R)
  156. <span style="font-variant:small-caps; ">d</span>-Cycloserine Facilitation of Exposure Therapy Improves Weight Regain in Patients With Anorexia Nervosa
  157. Clarifying the Behavioral Economics of Social Anxiety Disorder
  158. Effect of Physical Activity, Social Support, and Skills Training on Late-Life Emotional Health: A Systematic Literature Review and Implications for Public Health Research
  159. Association of Functional Polymorphisms from Brain-Derived Neurotrophic Factor and Serotonin-Related Genes with Depressive Symptoms after a Medical Stressor in Older Adults
  160. Response to Mohler and Colleagues
  161. Effects of Mindfulness Based Stress Reduction Therapy on Subjective Bother and Neural Connectivity in Chronic Tinnitus
  162. Ecological Momentary Assessment of Tinnitus Using Smartphone Technology
  163. A Novel Treatment for Tinnitus and Tinnitus-Related Cognitive Difficulties Using Computer-Based Cognitive Training and D-Cycloserine
  164. Short-term affective recovery from hip fracture prospectively predicts depression and physical functioning.
  165. Common Selective Serotonin Reuptake Inhibitor Side Effects in Older Adults Associated with Genetic Polymorphisms in the Serotonin Transporter and Receptors: Data from a Randomized Controlled Trial
  166. How bandwidth selection algorithms impact exploratory data analysis using kernel density estimation.
  167. Safety, Tolerability, and Clinical Effect of Low-Dose Buprenorphine for Treatment-Resistant Depression in Midlife and Older Adults
  168. Development and Testing of Treatments
  169. Planning Grants
  170. Depression, Antidepressants, and Bone Health in Older Adults: A Systematic Review
  171. Combiningd-cycloserine with motor training does not result in improved general motor learning in neurologically intact people or in people with stroke
  172. Patient Active Time During Therapy Sessions in Postacute Rehabilitation: Development and Validation of a New Measure
  173. Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone
  174. Mindfulness-based stress reduction for older adults with worry symptoms and co-occurring cognitive dysfunction
  175. Dynamic Prediction of Treatment Response in Late-Life Depression
  176. Is There a Role for Antidepressant and Antipsychotic Pharmacogenetics in Clinical Practice in 2014?
  177. Validation of the Ambivalent and Purposeful Engagement – Trait Measure
  178. Anxiety Disorders
  179. Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults
  180. Anxiety Disorders in Older Adults: Looking to DSM5 and Beyond…
  181. Antidepressant Medication Augmented With Cognitive-Behavioral Therapy for Generalized Anxiety Disorder in Older Adults
  182. Research to Reduce the Suicide Rate Among Older Adults: Methodology Roadblocks and Promising Paradigms
  183. Association of cortisol with neuropsychological assessment in older adults with generalized anxiety disorder
  184. Lessons Learned Fromd-Cycloserine: The Promise and Limits of Drug Facilitation of Exposure Therapy
  185. Enhanced Medical Rehabilitation Is Feasible in a Skilled Nursing Facility: Preliminary Data on a Novel Treatment for Older Adults With Depression
  186. Serotonin–norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorption
  187. A HIGH-THROUGHPUT CLINICAL ASSAY FOR TESTING DRUG FACILITATION OF EXPOSURE THERAPY
  188. Enhanced Medical Rehabilitation Increases Therapy Intensity and Engagement and Improves Functional Outcomes in Postacute Rehabilitation of Older Adults: A Randomized-Controlled Trial
  189. Functional network dysfunction in anxiety and anxiety disorders
  190. Measuring Treatment Fidelity in a Rehabilitation Intervention Study
  191. Reversal of SSRI-Associated Urinary Retention With Mirtazapine Augmentation
  192. Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors
  193. Comorbid anxiety and depression: bête noire or quick fix?
  194. Memantine for late‐life depression and apathy after a disabling medical event: a 12‐week, double‐blind placebo‐controlled pilot study
  195. Inflammatory Cytokine Levels and Depressive Symptoms in Older Women in the Year After Hip Fracture: Findings from the Baltimore Hip Studies
  196. Changes in neuropsychological functioning following treatment for late-life generalised anxiety disorder
  197. Improving recognition of late life anxiety disorders in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition: observations and recommendations of the Advisory Committee to the Lifespan Disorders Work Group
  198. Treatment‐related alteration of cortisol predicts change in neuropsychological function during acute treatment of late‐life anxiety disorder
  199. Elevated Cortisol in Older Adults With Generalized Anxiety Disorder Is Reduced by Treatment: A Placebo-Controlled Evaluation of Escitalopram
  200. Treating Depression in Older Adults with Dementia
  201. Anxiety Disorders: New Developments in Old Age
  202. Altered cerebral blood flow patterns associated with pathologic worry in the elderly
  203. Maintenance Treatment of Depression in Old Age
  204. Relation of Serotonin Transporter Genetic Variation to Efficacy of Escitalopram for Generalized Anxiety Disorder in Older Adults
  205. Augmenting antidepressant medication with modular CBT for geriatric generalized anxiety disorder: a pilot study
  206. Treating depression to remission in older adults: a controlled evaluation of combined escitalopram with interpersonal psychotherapy versus escitalopram with depression care management
  207. Anxiety disorders in older adults: a comprehensive review
  208. Cognitive and Affective Predictors of Rehabilitation Participation After Stroke
  209. Use of the Late‐Life Function and Disability Instrument to Assess Disability in Major Depression
  210. Escitalopram modestly improves generalised anxiety disorder in older adults in treatment completers
  211. fMRI activation in late‐life anxious depression: a potential biomarker
  212. Apathy After Hip Fracture: A Potential Target for Intervention to Improve Functional Outcomes
  213. The Burden of Late-Life Generalized Anxiety Disorder: Effects on Disability, Health-Related Quality of Life, and Healthcare Utilization
  214. Escitalopram Treatment of Generalized Anxiety Disorder in Older Adults—Reply
  215. Patient Participation and Physical Activity During Rehabilitation and Future Functional Outcomes in Patients After Hip Fracture
  216. Aripiprazole Prescribing Patterns and Side Effects in Elderly Psychiatric Inpatients
  217. High worry severity is associated with poorer acute and maintenance efficacy of antidepressants in late-life depression
  218. Pilot Study of Augmentation With Aripiprazole for Incomplete Response in Late-Life Depression
  219. Escitalopram for Older Adults With Generalized Anxiety Disorder
  220. The utility of the Generalized Anxiety Disorder Severity Scale (GADSS) with older adults in primary care
  221. Association of serotonin-1A and 2A receptor promoter polymorphisms with depressive symptoms and functional recovery in elderly persons after hip fracture
  222. Generalized Anxiety Disorder Severity Scale Validation in Older Adults
  223. Do Clinical Rehabilitation Education Programs Really Improve Stroke-Related Knowledge?
  224. Bringing the bedside to the bench, and then to the community: a prospectus for intervention research in late‐life anxiety disorders
  225. Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder
  226. Rescue Pharmacotherapy With Duloxetine for Selective Serotonin Reuptake Inhibitor Nonresponders in Late-Life Depression
  227. An Open-Label Pilot Study of Acetylcholinesterase Inhibitors to Promote Functional Recovery in Elderly Cognitively Impaired Stroke Patients
  228. Residual symptoms and recurrence during maintenance treatment of late-life depression
  229. Biomarkers in Geriatric Psychiatry
  230. Stroke-Related Knowledge and Health Behaviors Among Poststroke Patients in Inpatient Rehabilitation
  231. Maintenance Treatment for Old‐Age Depression Preserves Health‐Related Quality of Life: A Randomized, Controlled Trial of Paroxetine and Interpersonal Psychotherapy
  232. Depressive symptoms in late life: associations with apathy, resilience and disability vary between young‐old and old‐old
  233. Preventing Depression in Medical Illness
  234. Cognitive Impairment in Late-Life Generalized Anxiety Disorder
  235. Recovery From Major Depression in Older Adults Receiving Augmentation of Antidepressant Pharmacotherapy
  236. Predicting 6‐week treatment response to escitalopram pharmacotherapy in late‐life major depressive disorder
  237. Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study
  238. Does depression, apathy or cognitive impairment reduce the benefit of inpatient rehabilitation facilities for elderly hip fracture patients?
  239. Onset of Depression in Elderly Persons After Hip Fracture: Implications for Prevention and Early Intervention of Late‐Life Depression
  240. Impact of Prior Treatment Exposure on Response to Antidepressant Treatment in Late Life
  241. The Relationship Between Pain and Mental Flexibility in Older Adult Pain Clinic Patients
  242. Influence of Rehabilitation Site on Hip Fracture Recovery in Community-Dwelling Subjects at 6-Month Follow-Up
  243. Maintenance Treatment of Major Depression in Old Age
  244. Outcomes of Late-Life Anxiety Disorders During 32 Weeks of Citalopram Treatment
  245. Evidence-Based Treatment of Geriatric Anxiety Disorders
  246. Predictors of Adequacy of Depression Management in the Primary Care Setting
  247. Dr. Lenze and Colleagues Reply
  248. Conclusions Inconsistent With Results With Citalopram
  249. Somatic symptoms of depression in elderly patients with medical comorbidities
  250. Comorbid anxiety disorder in late life depression: association with memory decline over four years
  251. Somatic Symptoms in Late-Life Anxiety: Treatment Issues
  252. Association of the Serotonin Transporter Gene-Linked Polymorphic Region (5-HTTLPR) Genotype With Depression in Elderly Persons After Hip Fracture
  253. The Course of Functional Decline in Older People with Persistently Elevated Depressive Symptoms: Longitudinal Findings from the Cardiovascular Health Study
  254. Effect of rehabilitation site on functional recovery after hip fracture
  255. Efficacy and Tolerability of Citalopram in the Treatment of Late-Life Anxiety Disorders: Results From an 8-Week Randomized, Placebo-Controlled Trial
  256. Generalized Anxiety Disorder in Late Life: Lifetime Course and Comorbidity With Major Depressive Disorder
  257. Significance of poor patient participation in physical and occupational therapy for functional outcome and length of stay
  258. Adverse effects of depression and cognitive impairment on rehabilitation participation and recovery from hip fracture
  259. The Pittsburgh Rehabilitation Participation Scale: reliability and validity of a clinician-rated measure of participation in acute rehabilitation
  260. Time Course of Response to Antidepressants in Late-Life Major Depression
  261. Achieving Long-Term Optimal Outcomes in Geriatric Depression and Anxiety
  262. Good treatment outcomes in late-life depression with comorbid anxiety
  263. Treatment Considerations for Anxiety in the Elderly
  264. Poster 74
  265. Comorbidity of depression and anxiety in the elderly
  266. Anxiety Disorders in Late Life: An Evolving Picture
  267. Risk Factors for Falls During Treatment of Late-Life Depression
  268. Clinically Relevant Behaviors in Elderly Hip Fracture Inpatients
  269. Effect of Cerebrovascular Risk Factors on Depression Treatment Outcome in Later Life
  270. Combined Pharmacotherapy and Psychotherapy as Maintenance Treatment for Late-Life Depression: Effects on Social Adjustment
  271. Anxiety Symptoms in Elderly Patients with Depression
  272. Subjective health measures and acute treatment outcomes in geriatric depression
  273. The Association of Late-Life Depression and Anxiety With Physical Disability: A Review of the Literature and Prospectus for Future Research
  274. Comorbidity of depression and anxiety disorders in later life
  275. Comorbid Anxiety Disorders in Depressed Elderly Patients
  276. White Matter Hyperintensities and Gray Matter Lesions in Physically Healthy Depressed Subjects
  277. Psychiatric Symptoms Endorsed by Somatization Disorder Patients in a Psychiatric Clinic
  278. Reactivation of Latent Herpes Simplex Virus by Excimer Laser Photokeratectomy